<DOC>
	<DOCNO>NCT00087945</DOCNO>
	<brief_summary>The way abacavir ( ABC ) behave body differs child adult , little known ABC adolescent . It unclear adult dos ABC appropriate adolescent . The purpose study determine blood level ABC HIV infect adolescent ABC-containing regimen .</brief_summary>
	<brief_title>Blood Levels Abacavir HIV Infected Adolescents</brief_title>
	<detailed_description>ABC approve treatment HIV adult child , unclear currently recommend ABC dos appropriate adolescent . Previous data suggest ABC clearance child twice find adult , limited data exist pharmacokinetics ABC adolescent . This study evaluate 8-hour pharmacokinetics ABC HIV infect adolescent currently ABC-containing treatment regimen . There two group study . Group 1 participant 13 17 year old . Group 2 participant 18 25 year old . All participant receive 300 mg dose ABC either single-agent tablet combination tablet ABC , lamivudine , zidovudine ( whichever currently take ) . Participants medical history assessment physical exam screen study entry . Participants also ask adherence ABC-containing regimen study entry . During 8-hour drug level study , blood collection pharmacokinetic analysis occur prior take ABC , 0.5 , 1 , 2 , 3 , 4 , 6 , 8 hour take ABC .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV1 infect CD4 count great 100 cells/mm3 Viral load le 100,000 copies/ml Have take abacavircontaining regimen least 8 week prior study entry Weight 83 lb ( 37.5 kg ) Ability willingness swallow study medication Consent parent guardian , applicable Any Grade 3 great toxicity within 14 day prior study entry Participation PACTG P1018 CDC Category C opportunistic infection HIV1 associate cancer require drug therapy time study enrollment Treatment immune modulators , include interleukin2 intravenous gamma globulin , within 30 day study entry Received therapeutic vaccine HIV1 vaccine give primary prevention within 30 day study entry Surgical medical problem affect gastrointestinal motility absorption ( e.g. , ileus , ulcerative colitis ) liver function History chronic alcohol use Any clinically significant disease HIV1 infection , investigator 's opinion , would represent increase risk participant compromise outcome study Chemotherapy active cancer Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>